REQUEST A DEMO
Total
USD $0.00
Search more companies

Vaxcell-Bio Co.,Ltd. (South Korea)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Vaxcell-Bio Co.,Ltd. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in the research and development of anti-angiogenic immunotherapy drugs. The Company s pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The Company sells its products in domestic and overseas markets.

Headquarters
12-55, Sandan-Gil, Hwasun-Eup
Hwaseong; Gyeonggi;

Contact Details: Purchase the Vaxcell-Bio Co.,Ltd. report to view the information.

Website: http://www.vaxcell-bio.com

Basic Information
Total Employees:
Purchase the Vaxcell-Bio Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Vaxcell-Bio Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Vaxcell-Bio Co.,Ltd. report to view the information.
Incorporation Date:
February 18, 2010
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
㈜박셀바이오
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
No results were found for this company.

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?